The issue of prostate cancer screening with prostate-specific antigen (PSA) has been contentious for nearly two decades due to lack of data from randomized trials, but that has now changed.A brief review of the available data is warranted as there is finally some clarity on this critically important topic.Knowing what to ignore, as well as what to focus on, is critical for understanding the current data.